|
|
Recently, Qishi Biotech's independently developed Qishi IgY Antibody Oral Bacteriostatic Spray successfully passed the product inspection by Guangdong Provincial Microbial Analysis and Testing Center. The IgY antibody spray can prevent respiratory infectious diseases and has a long-lasting effect on mucous membranes. Certified by authoritative institutions, it effectively prevents virus entry! National Accreditation Laboratory (CNAS) Certified by authoritative institutions Antimicrobial spray of anti COVID-19 IgY antibody Report on neutralizing the coronavirus in the air
Experimental evidence: Qishi IgY Antibody Oral Bacteriostatic Spray, an immune protective disinfectant made with a broad-spectrum anti-COVID-19 IgY antibody as the active ingredient, can effectively neutralize 99.99% of the coronavirus in the air!
IgY Neutralizing Antibody Oral Bacteriostatic Spray: 24-Hour Protection for Your Health IgY immunoglobulin is a natural ingredient that is safe and has no side effects. It is reliable and efficient, with high activity, effectively preventing the invasion of COVID-19. It can be stored at room temperature, is small and easy to carry, and can be used whenever needed. It is suitable for all age groups. Shenzhen Qishi's broad-spectrum anti-mutated coronavirus and influenza virus composite antibodies can be used for the prevention of COVID-19 infection and influenza, as well as epidemic prevention and control. Swedish scientists have demonstrated through experiments that the main route of lung infection is through the mouth and nose. IgY antibodies can prevent respiratory tract infections and have a long-lasting effect on mucous membranes; therefore, they are made into oral spray and nasal spray. Both COVID-19 and influenza viruses multiply and gather in the throat, and then spread to the lungs and other organs through the lower respiratory tract. By spraying the antibodies directly on the mucous membranes of the mouth, nose, and throat, where the virus enters the respiratory tract, IgY antibodies can establish the first line of defense, block the virus invasion pathway, and effectively prevent infection. It can also compensate for the limitations of vaccines in producing less antibodies in the nasal and upper respiratory tract, and the risk of breakthrough infections. |
